EN DE
STOCK COMPARISON

Innova Captab vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how Innova Captab (INNOVACAP) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 17, 2026.

As of Aug 17, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: Innova Captab trades at ₹1,036 versus a fair value of ₹430 (-59%), while Jiangsu Hengrui Medicine Co trades at ¥52.62 versus ¥25.94 (-51%).
Innova Captab
INNOVACAP.NSE · INR · Health Care
-59%
upside to fair value
overvalued
Price₹1,036
Fair Value₹430
Quality51/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-51%
upside to fair value
overvalued
Price¥52.62
Fair Value¥25.94
Quality66/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Innova CaptabJiangsu Hengrui Medicine Co
Valuation
42.1×P/E (TTM)43.6×
3.44×P/S (TTM)10.84×
5.14×P/B5.76×
25.2×EV/EBITDA33.0×
PEG0.93×
0.3%Dividend yield0.4%
₹3.00Dividend per share¥0.20
Profitability
9%Net margin25%
10%Operating margin32%
14%Return on equity15%
7%Return on assets9%
Growth
42%Revenue growth (YoY)13%
20.1%Avg. growth/yr (3Y)13.9%
31.4%Avg. growth/yr (5Y)2.5%
Balance & size
0.20×Debt / equity
$589MMarket cap$52B
expensiveGrowth qualityhealthy

Innova Captab leads: 7 to 5 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Innova Captabof which business quality 51 · market factors 75 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 42
ProfitabilityMargins and returns on capital today
53
63
Quality GrowthAre margins and returns improving?
60
41
CashflowEarnings quality: real cash, not paper profit
18
82
Fin. StrengthBalance sheet, leverage, solvency risk
68
100
InvestmentDisciplined investing over empire-building
29
27
Low VolatilityCalm price path (market factor)
79
79
MomentumPrice trend over the last 3–12 months (market factor)
73
31
52W MomentumDistance to the 52-week high (market factor)
75
20
Net IssuanceBuybacks instead of dilution
82
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Innova Captab

DCF Models₹592
Earnings-Based₹558
Dividend Discount₹35.19
Multiples₹435
Asset-Based₹128
Growth DCF₹312
Economic Profit₹209
Growth Earnings₹750

25 of 26 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.78
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥23.65
Asset-Based¥6.44
Growth DCF¥39.88
Economic Profit¥18.21
Growth Earnings¥30.99

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Innova Captab
Bear ₹187Fair Value ₹430Bull ₹552
₹1,036 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥32.81
¥52.62 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Innova Captab · Health Care

Quality score51 · below median
Fair value upside-59% · below median

Jiangsu Hengrui Medicine Co · Health Care

Quality score66 · Top 25%
Fair value upside-51% · below median

Bottom line

As of Aug 17, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: Innova Captab trades at ₹1,036 versus a fair value of ₹430 (-59%), while Jiangsu Hengrui Medicine Co trades at ¥52.62 versus ¥25.94 (-51%).

Jiangsu Hengrui Medicine Co has the higher quality score (66/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.